NR3C2 and Hypertension: In patients with mineralocorticoid receptor antagonist-resistant hypertension, BP control was achieved in 43.6% vs. 28.4% of patients treated with valsartan alone (adjusted OR 2.63; CI: 1.18–5.89) (38).